Apyx Medical vs LENSAR
LENSAR reported revenue of $58 million in fiscal 2025, about the same as Apyx Medical's $53 million in fiscal 2025. Apyx Medical's revenue grew 9.9% in its latest year, and LENSAR's grew 9.2%. Apyx Medical had an operating margin of -12.2%, against -42.1% at LENSAR. Free cash flow was −$9 million at Apyx Medical and −$15 million at LENSAR.
Side by side
| Apyx Medical | LENSAR | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $53M | $58M |
| Revenue growth | 9.9% | 9.2% |
| Revenue growth a year, last 5 years | 13.8% | 17.2% |
| Gross margin | 62.5% | 46.4% |
| Operating margin | −12.2% | −42.1% |
| Net margin | −21.2% | −58.7% |
| Free cash flow | −$9M | −$15M |
| Free cash flow margin | −17.2% | −25.5% |
| Return on capital | −25.0% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.6% | 3.8% |
| Last close | $2.39 | $4.64 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $169,989 |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Apyx MedicalLENSAR
Operating margin
Percent of revenue
Apyx MedicalLENSAR
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Apyx MedicalLENSAR
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Apyx Medical and LENSAR pages.